PDGFRB promotes dedifferentiation and pulmonary metastasis through rearrangement of cytoskeleton under hypoxic microenvironment in osteosarcoma

  • 0Department of Orthopedic Surgery, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200072, PR China; Institute of Bone Tumor Affiliated to Tongji University School of Medicine, Shanghai 200072, PR China.

|

|

Summary

This summary is machine-generated.

Hypoxia promotes osteosarcoma dedifferentiation and metastasis. Hypoxia inducible factor 1 subunit alpha (HIF1A) upregulates platelet derived growth factor receptor beta (PDGFRB), driving cancer cell changes and spread.

Area Of Science

  • Oncology
  • Cell Biology
  • Molecular Biology

Background

  • Osteosarcoma (OS) frequently exhibits hypoxia and dedifferentiation, correlating with poor patient outcomes.
  • Understanding the molecular mechanisms linking hypoxia to OS dedifferentiation is critical for improving treatment strategies.

Purpose Of The Study

  • To elucidate the role of hypoxia in osteosarcoma dedifferentiation.
  • To identify key signaling pathways involved in hypoxia-induced OS dedifferentiation and metastasis.

Main Methods

  • Sphere formation assays to identify dedifferentiated cells.
  • RNA interference (RNAi) to investigate the HIF1A-PDGFRB axis.
  • Analysis of signaling molecules (PDGFRB, FAK, RhoA, MLC2) and cytoskeleton dynamics.
  • In vitro (wound healing, Transwell) and in vivo (pulmonary metastasis) assays to assess OS cell migration and invasion.

Main Results

  • Dedifferentiated OS cells showed elevated HIF1A and PDGFRB expression.
  • HIF1A positively regulated PDGFRB, activating RhoA and MLC2 phosphorylation.
  • PDGFRB enhanced FAK phosphorylation, altered cell morphology, and promoted actin cytoskeleton rearrangement.
  • PDGFRB significantly increased OS cell migration, invasion, and pulmonary metastasis.

Conclusions

  • Hypoxia-inducible factor 1 subunit alpha (HIF1A) upregulates platelet-derived growth factor receptor beta (PDGFRB) in hypoxic osteosarcoma.
  • PDGFRB signaling, involving RhoA and cytoskeleton modulation, drives OS dedifferentiation and metastasis.
  • Targeting the HIF1A-PDGFRB pathway may offer therapeutic potential for osteosarcoma.